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Background
The treatment of diabetic foot lesions need medications
capable of managing wound infection and exudates that,
variously combined, can influence the natural history of
the pathology and therefore limb survival. A particular
and economic device, is represented by honeycomb
structure polyurethane foam Ligasano ©.
Material and methods
We evaluated 5 patients with a diabetic foot and a case
history of infected wounds until flemmone. The lesions
have been debrided and/or surgically drained and then
medicated three time a week, with variable thickness
Ligasano (0,5 and 1 cm). Tissue sample was collected to
perform colture and antibiogram. According to diabetic
foot guidelines of Consensus Conference 2003 patients
(3 male and 2 female – mean age 54,3 years) were
affected by skin lesions of the foot and were classified as
in Table 1. Medications were performed until the reduc-
tion and/or complete healing.
Results
The patients have been medicated once a day for 10 days
(2, 5) and/or once every three weeks (3/5) for the first
two months. The mean time of the treatment was of
196 day for 4 patients. In 1 patient a minor cardiovascu-
lar event occurred and time of therapy was 296 days.
Conclusions
In our experience the device was proved to be economic
and manageable, allowing the management of the exu-
dates and avoiding, at the same time, the involvement of
the perilesional skin that constitutes itself an innovation
on the treatment of diabetic foot lesion.
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Figure 1 Plantar lesion.
Table 1
Complications Number of patients
glycometabolic failure 4/5
cardiovascular complications 3/5
kidney disease 1/5
rethinic disease 2/5
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Figure 4 Flemmone of the left foot surgically drained and treated with antibiotic therapy and intracavitary Ligasano.
Figure 3 Infected lesion with tendons exposure.
Figure 2 Infected lesion of the dorsum of the foot onset because the patient wears unqualified shoe.
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